Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.85 |
| ▸ | TK2 | O00142 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679403 | 1.00 | TK1 (0.85) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL11354411 | 0.99 | TK1 (0.84) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13273343 | 0.97 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13252712 | 0.97 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13273573 | 0.97 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL1532524 | 0.97 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL1532525 | 0.97 | TK1 (0.87) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL13273340 | 0.92 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL5982016 | 0.92 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 | |
| SCHEMBL2396529 | 0.92 | TK1 (1.00) | TK1TK2LMNASMN1; SMN2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060029667-A1 | polyoxyethylene glycol having multiple functional groups, at least one of which is covalently bound to a therapeutic or diagnostic agent (peptide) , and a cell uptake promoter (formyl-met-leu-phe)covalently bound to the therapeutic or diagnostic agent; conjugates; pharmacokinetic; bioavailability | RAMANATHAN SRINIVASAN | 2006-02-09 | — | — | US | claimed |
| US-20030091640-A1 | Bioavailability | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-05-15 | — | — | US | claimed |
| WO-2002062396-A2 | ENHANCED ORAL AND TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGNOSTIC AGENTS USING POLYMER CONJUGATES | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2002-08-15 | — | — | WO | claimed |
| US-9943606-B2 | Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9421272-B2 | Nanocarrier compositions and methods | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150196657-A1 | Dendritic Polypeptide-Based Nanocarriers for the Delivery of Therapeutic Agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2015-07-16 | — | — | US | disclosed |
| US-20130072447-A1 | ENHANCED ORAL TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGANOSTIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120093723-A1 | NANOCARRIER COMPOSITIONS AND METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110087004-A1 | ENHANCED ORAL TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGNOSTIC AGENTS | RAMANATHAN SRINIVASAN | 2011-04-14 | — | — | US | disclosed |
| US-7740882-B2 | polyoxyethylene glycol having multiple functional groups, at least one of which is covalently bound to a therapeutic or diagnostic agent (peptide) , and a cell uptake promoter (formyl-met-leu-phe)covalently bound to the therapeutic or diagnostic agent; conjugates; pharmacokinetic; bioavailability | RAMANATHAN SRINIVASAN | 2010-06-22 | — | — | US | disclosed |
| EP-1848463-A2 | METHOD OF CONJUGATING AMINOTHIOL CONTAINING MOLECULES TO VEHICLES | Amgen Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060029667-A1 | polyoxyethylene glycol having multiple functional groups, at least one of which is covalently bound to a therapeutic or diagnostic agent (peptide) , and a cell uptake promoter (formyl-met-leu-phe)covalently bound to the therapeutic or diagnostic agent; conjugates; pharmacokinetic; bioavailability | RAMANATHAN SRINIVASAN | 2006-02-09 | — | — | US | disclosed |
| US-20030091640-A1 | Bioavailability | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-05-15 | — | — | US | disclosed |
| WO-2002062396-A2 | ENHANCED ORAL AND TRANSCOMPARTMENTAL DELIVERY OF THERAPEUTIC OR DIAGNOSTIC AGENTS USING POLYMER CONJUGATES | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-0923596-A2 | LIPOPHILIC OLIGONUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5763208-A | Oligonucleotides and their analogs capable of passive cell membrane permeation | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1998004575-A2 | LIPOPHILIC OLIGONUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| US-5633360-A | CONTAINS AT LEAST TWO NUCLEOSIDE RESIDUES AND INTERNUCLEOTIDE LINKAGES | GILEAD SCIENCES, INC. (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1992014842-A1 | APTAMERS SPECIFIC FOR THROMBIN AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| US-4271153-A | VIRICIDES - TO COMBAT HERBES VIRUS | ROBUGEN GMBH PHARMAZEUTISCHE FABRIK (DE) | 1981-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093723-A1 | NANOCARRIER COMPOSITIONS AND METHODS | HDGF, IAPP, LNPEP | TK1 2128/4885TK2 2651/4885LMNA 617/4885 |
| US-20150196657-A1 | Dendritic Polypeptide-Based Nanocarriers for the Delivery of Therapeutic Agents | CD2BP2, DCLRE1B, LNPEP | TK1 369/4885TK2 1284/4885LMNA 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.